SymbolBSEM
NameBIOSTEM TECHNOLOGIES, INC.
SectorUNDEFINED
RegionNorth America
Industry-
Address33064 United States FL 2836 Center Port Circle
Telephone+1 954-380-8342
Fax
Email
Websitehttp://www.biostemtechnologies.com
IncorporationUS
Incorporated On2009
Employees
Fiscal Year12/31
Public Since
ExchangesOTC
AuditorCBIZ CPAs P.C.;
Audit StatusUNAUDITED
Reporting StatusAlternative Reporting Standard
CIK0001658678
Description

BioStem Technologies is a leading innovator focused on harnessing the natural properties
of perinatal tissue in the development, manufacture, and commercialization of allografts
for regenerative therapies. The Company is focused on manufacturing products that
change lives, leveraging its proprietary BioRetain processing method. BioRetain has
been developed by applying the latest research in regenerative medicine, focused on
maintaining growth factors and preserving tissue structure. BioStem Technologies quality management system and standard operating procedures have been reviewed and
accredited by the American Association of Tissue Banks ("AATB"). These systems and
procedures are established per current Good Tissue Practices ("cGTP") and current Good
Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE,
VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is
processed at the Companys FDA registered and AATB accredited site in Pompano
Beach, Florida.

Additional info from OTC:
BioStem Technologies is a leading innovator focused on harnessing the natural properties
of perinatal tissue in the development, manufacture, and commercialization of allografts
for regenerative therapies. The Company is focused on manufacturing products that
change lives, leveraging its proprietary BioRetain processing method. BioRetain has
been developed by applying the latest research in regenerative medicine, focused on
maintaining growth factors and preserving tissue structure. BioStem Technologies quality management system and standard operating procedures have been reviewed and
accredited by the American Association of Tissue Banks ("AATB"). These systems and
procedures are established per current Good Tissue Practices ("cGTP") and current Good
Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE,
VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is
processed at the Companys FDA registered and AATB accredited site in Pompano
Beach, Florida.

2026-07-29 20:05

BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026

Read more
2026-06-10 20:05

BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference

Read more
2026-06-09 11:00

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

Read more
2026-05-22 11:00

BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor

Read more
2026-05-20 13:00

BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent

Read more
2026-04-30 20:05

BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026

Read more
2026-03-24 20:05

BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results

Read more
2026-03-23 15:40

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair

Read more
2026-03-23 11:00

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair

Read more
2026-03-11 20:05

BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026

Read more